The BLA is supported by the primary analysis data of the IGNYTE trial, evaluating RP1 combined with nivolumab in patients with anti-PD-1 failed melanoma. A confirmatory Phase 3 trial, IGNYTE-3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback